Behold.ai red dot
Medical imaging AI platform for chest X-ray and CT workflows, with FDA-cleared red dot pneumothorax triage and Behold.ai-marketed lung cancer and CT head pathway modules.
Last updated: June 8, 2026
Back to directoryAI brain MRI software portfolio that quantifies and compares neurological imaging findings to support radiologist- and neurologist-reviewed care workflows.
Programs that need standardized quantitative brain MRI reports for multiple sclerosis, dementia, ARIA, traumatic brain injury, epilepsy, Parkinson's disease, or brain tumor follow-up with specialist review.
Compare within workflow: Medical imaging and radiology · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating icometrix icobrain as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat icobrain as regulated medical image-processing software and match each deployment to the exact 510(k), software version, measured brain structures, disease module, intended user, region, and clinical workflow before using outputs in care decisions. |
|---|---|
| Privacy | Review DICOM pseudonymization, retained demographics, transfer encryption, remote icobridge access, cloud or local processing, support access, retention, audit logs, HIPAA/GDPR claims, ISO27001 scope, BAA or DPA terms, and re-identification controls. |
| Evidence | Evaluate icometrix publications and FDA summaries against the local scanner mix, MRI protocols, disease population, longitudinal interval, lesion and volume thresholds, ARIA workflow, false positives, false negatives, and specialist interpretation process. |
| Workflow | Best governed as quantitative MRI support for radiologists and neurologists, with explicit report-review responsibility, escalation rules for new activity or ARIA findings, treatment-decision boundaries, and post-deployment performance monitoring. |
icometrix describes icobrain as validated, FDA-cleared brain MRI AI software for comparing and quantifying neurological scans over time, with disease-specific reports across MS, dementia and Alzheimer's, ARIA, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors; FDA records list multiple icobrain 510(k) clearances for radiological image-processing software, while icobridge materials describe DICOM pseudonymization, TLS transfer, HIPAA/GDPR handling, and ISO27001 certification.
Not for: Standalone neurological diagnosis, replacing radiology interpretation, unsupported MRI protocols or disease modules, treatment decisions without clinician review, or assuming every icobrain report has identical FDA clearance.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.